Teva Announced Saturday, Switching To UZEDY At Four Weeks After The Last Dose Of Once-monthly Paliperidone Palmitate Provided The Most Comparable Pharmacokinetic Profile Based On The Relevant PK Modeling Data For Schizophrenia
Teva Announced Saturday, Switching To UZEDY At Four Weeks After The Last Dose Of Once-monthly Paliperidone Palmitate Provided The Most Comparable Pharmacokinetic Profile Based On The Relevant PK Modeling Data For Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly intramuscular injection of Invega Sustenna. The results were presented at the Psych Congress Elevate 2024 Annual Meeting taking place from May 30 – June 2 in Las Vegas, Nevada.
梯瓦制药工业有限公司（纽约证券交易所和TASE：TEVA）的美国子公司梯瓦制药今天宣布介绍其长效注射剂（LAI）精神分裂症研究计划的七项研究。演示内容包括为患者转用UZEDY的临床策略提供信息的数据，UZEDY是一种每隔一两个月皮下使用一次的利培酮缓释注射悬浮液，用于治疗成人精神分裂症，该药物来自每月一次的肌肉注射Invega Sustenna。研究结果已在5月30日至6月2日在内华达州拉斯维加斯举行的2024年心理大会 Elevate 年会上公布。
译文内容由第三方软件翻译。